High loading dose of clopidogrel in patients undergoing percutaneous coronary intervention
Journal Title: Przewodnik Lekarza - Year 2005, Vol 78, Issue 6
Abstract
In recent years in Poland a great development of interventional treatment of patients with acute coronary syndromes (ACS) has been seen. Since the publication of the CURE study, on the treatment of ACS patients, and the analysis of a subgroup treated with percutaneous coronary intervention (PCI) a loading dose of 300 mg of clopidogrel has become a routine practice. The later studies though, revealed that such a dose, given immediately before or during the intervention is not sufficient to reduce significantly the risk of periprocedural ischemic complications. One of the possible solutions may be to delay the intervention for several hours after clopidogrel pretreatment. Since in the most of ACS patients a clear benefit of immediate intervention has been demonstrated, the new studies on the higher dosing were started. Those studies, including low- as well as high-risk patients undergoing PCI in stable angina or in non-ST elevation ACS revealed a significant advantage of a loading dose of 600 mg, with acceptable risk of bleeding complications. Although none such a study (with a dose of 600 mg) has been performed yet in patients with ST elevation ACS, the two recent studies have demonstrated significant advantage of clopidogrel 300 mg over placebo, and there is no reason to claim that the higher dose will be not beneficial in this high-risk population. In the last ESC PCI guidelines there is a recommendation IC that a clopidogrel loading dose of 600 mg should be preferred in patients, both with and without ST-elevation ACS if pretreatment with the drug can not be initiated at least 6 hours prior to intervention. Given the efficacy and safety of the higher dose of clopidogrel, we are convinced that in the „real world” setting, the best option could be a prehospital pretreatment with 600 mg of clopidogrel in all ACS patients.
Authors and Affiliations
Stefan Grajek, Maciej Lesiak
Keywords
Related Articles
- EP ID EP139081
- DOI -
- Views 111
- Downloads 0
Ocena działania i tolerancji preparatu Soyfem u kobiet we wczesnym okresie pomenopauzalnym
Przeprowadzono randomizowane badania kliniczne przez 12 mies. u 71 kobiet we wczesnym okresie pomenopauzalym, które stosowały preparat Soyfem firmy Biofarm. Badania biochemiczne przeprowadzone zostały po 3 mies. stosow...
Difficult diabetes - essence of disease or healthy behaviour?
Some of the patients with diabetes suffer chronically poor diabetic control. These patients cannot be controlled adequately, even by closed supervised, intensive insulin regimens. Obesity, puberty (due mainly to increase...
Wilm\'s tumor relapses in children were treated in Department of Children Surgery in Katowice in the last 11 years from 1992 to 2003
From 1992 to 2003 year in the Department of Children Surgery in Katowice were undergoing a treatment of 108 children with Wilm’s tumor in age between 6 month and 16 years. In 8 patients (7.4%) there were diagnosed anothe...
Szanowni Czytelnicy
Prewencja chorób układu sercowo-naczyniowego w podstawowej opiece zdrowotnej – punkt widzenia lekarza domowego
W artykule przedstawiono wyniki obejmujące analizę danych z kwestionariusza lekarza dołączonego do ankiet wysyłanych do lekarzy podstawowej opieki zdrowotnej (poz) w ramach badania POLKARD-SPOK (Standard podstawowej op...